UNSPSC 51422122: Mometasone furoate monohydrate

This classification denotes a therapeutic glucocorticoid C27H30Cl2O6.H2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier MTW0WEG809, chemically known as pregna-1,4-diene-3,20-dione, 9,21-dichloro-17-((2-furanylcarbonyl)oxy)-11-hydroxy-16-methyl-, (11.beta.,16.alpha.)- monohydrate, but more generally known as mometasone furoate monohydrate, which bears US NIH Compound Identifier 55188.

UNSPSC 51422122 Mometasone furoate monohydrate is a Commodity code nominally identifying a specific inhaled corticosteroid medication, yet recent state and local procurement activity under this code shows minimal relevant sourcing. The two most recent opportunities posted under the code—a Seminole County, Florida naloxone and drug deactivation systems IFB and a Texas Health and Human Services Commission RFI on direct-to-manufacturer pharmacy programs—do not align with procurement of mometasone furoate or corticosteroid inhalers. The mismatch suggests either miscoding by issuing bodies or that this Commodity code sees little active state and local use for its intended product line.

No recent opportunities directly soliciting mometasone furoate monohydrate appear in the available records. The Seminole County opportunity targets emergency-response medications (naloxone) and drug deactivation systems, while the Texas HHS RFI seeks information on pharmacy benefit program structure and direct-to-manufacturer contracting models rather than procurement of a specific pharmaceutical product. Business development professionals tracking this code should expect infrequent activity and verify that any future opportunities are properly coded before committing resources to pursuit.